

*This document is an English-translated version of an attachment of a notification for Revision of PRECAUTIONS issued by the Ministry of Health, Labour and Welfare.*

*This English version is intended to be a reference material to provide convenience for users.*

*In the event of inconsistency between the Japanese original and this English translation, the former shall prevail.*

# Revision of PRECAUTIONS

## Olaparib

March 17, 2026

### **Therapeutic category**

Other antitumor agents

### **Non-proprietary name**

Olaparib

### **Safety measure**

PRECAUTIONS should be revised.

*This document is an English-translated version of an attachment of a notification for Revision of PRECAUTIONS issued by the Ministry of Health, Labour and Welfare.  
 This English version is intended to be a reference material to provide convenience for users.  
 In the event of inconsistency between the Japanese original and this English translation, the former shall prevail.*

Revised language is underlined.

Current	Revision
<p>8. IMPORTANT PRECAUTIONS (N/A)</p> <p>11. ADVERSE REACTIONS 11.1 Clinically Significant Adverse Reactions (N/A)</p>	<p>8. IMPORTANT PRECAUTIONS <u>Hepatic impairment may occur. Liver function tests should be performed prior to and periodically during administration of this drug, and patients should be carefully monitored for their condition.</u></p> <p>11. ADVERSE REACTIONS 11.1 Clinically Significant Adverse Reactions <u>Hepatic impairment</u></p>

N/A: Not Applicable. No corresponding language is included in the current PRECAUTIONS.